Winfried Kern to Risk Assessment
This is a "connection" page, showing publications Winfried Kern has written about Risk Assessment.
Connection Strength
0.009
-
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 03; 21(1):470.
Score: 0.009